Catalyst overview
Research summary
This catalyst tracks a Phase 2 data readout for DT-168 in Fuchs Endothelial Corneal Dystrophy , Eye disease . The expected timing is based on the latest available company guidance and may change.
Cleared IND. 8/5/24- Initiate trial in 2024. 5/7/25- Favorable Ph1 data announced. 8/7/25- Ph2 biomarker study initiated. 11/05/25:- Ongoing Ph2 biomarker trial in FECD, data anticipated H2 2026. 03/09/26:- Ongoing Ph2 biomarker FECD trial; safety and biomarker data anticipated H2 2026. 04/28/26:- Ongoing Ph2 FECD biomarker trial; safety and biomarker data anticipated H2 2026. 08/03/26:- Ph2 FECD data delayed to 2027 due eye dropper supply.
Verification
Confirm timing and program details against the company announcement or filing.